[HTML][HTML] FGF/FGFR signaling in health and disease

Y Xie, N Su, J Yang, Q Tan, S Huang, M Jin… - Signal transduction and …, 2020 - nature.com
Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR)
signaling has crucial roles in a multitude of processes during embryonic development and …

Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies

BC Bernardo, KL Weeks, L Pretorius… - Pharmacology & …, 2010 - Elsevier
Cardiac hypertrophy can be defined as an increase in heart mass. Pathological cardiac
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …

Nitric oxide and peroxynitrite in health and disease

P Pacher, JS Beckman, L Liaudet - Physiological reviews, 2007 - journals.physiology.org
The discovery that mammalian cells have the ability to synthesize the free radical nitric oxide
(NO) has stimulated an extraordinary impetus for scientific research in all the fields of …

[HTML][HTML] Anti-apoptosis and cell survival: a review

L Portt, G Norman, C Clapp, M Greenwood… - … et Biophysica Acta (BBA …, 2011 - Elsevier
Type I programmed cell death (PCD) or apoptosis is critical for cellular self-destruction for a
variety of processes such as development or the prevention of oncogenic transformation …

Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury

E Murphy, C Steenbergen - Physiological reviews, 2008 - journals.physiology.org
Mitochondria play an important role in cell death and cardioprotection. During ischemia,
when ATP is progressively depleted, ion pumps cannot function resulting in a rise in calcium …

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

TF Chu, MA Rupnick, R Kerkela, SM Dallabrida… - The Lancet, 2007 - thelancet.com
Background Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approved by both
US and European Commission regulatory agencies for clinical use, extends survival of …

Controversies in ventricular remodelling

LH Opie, PJ Commerford, BJ Gersh, MA Pfeffer - The Lancet, 2006 - thelancet.com
Ventricular remodelling describes structural changes in the left ventricle in response to
chronic alterations in loading conditions, with three major patterns: concentric remodelling …

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

R Kerkelä, L Grazette, R Yacobi, C Iliescu, R Patten… - Nature medicine, 2006 - nature.com
Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the
causal agent in chronic myelogenous leukemia. Here we report ten individuals who …

The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury

T Kempf, M Eden, J Strelau, M Naguib… - Circulation …, 2006 - Am Heart Assoc
Data from the Women's Health Study show that serum levels of growth-differentiation factor-
15 (GDF-15), a distant member of the transforming growth factor-β superfamily, are an …

[HTML][HTML] Bone marrow mesenchymal stem cell-secreted exosomes carrying microRNA-125b protect against myocardial ischemia reperfusion injury via targeting SIRT7

Q Chen, Y Liu, X Ding, Q Li, F Qiu, M Wang… - Molecular and cellular …, 2020 - Springer
Abstract MicroRNA-125b (miR-125b) reduces myocardial infarct area and restrains
myocardial ischemia reperfusion injury (I/R). In this study, we aimed to investigate the effect …